首页> 外文期刊>Therapy >Colesevelam hydrochloride: a bile acid sequestrant for glycemic control and treatment of dyslipidemia in Type 2 diabetes mellitus
【24h】

Colesevelam hydrochloride: a bile acid sequestrant for glycemic control and treatment of dyslipidemia in Type 2 diabetes mellitus

机译:盐酸考来维仑:一种胆汁酸螯合剂,用于血糖控制和治疗2型糖尿病的血脂异常

获取原文
获取原文并翻译 | 示例
           

摘要

The complications of Type 2 diabetes mellitus (T2DM) include increased risk of macrovascular diseases such as coronary artery disease, stroke or peripheral vascular disease, and microvascular diseases such as retinopathy, neuropathy and nephropathy. The risk of macrovascular and microvascular diseases increases with the presence of dyslipidemia and hyperglycemia, respectively. Hence, treatment of T2DM must be aimed at treating hyperglycemia to prevent microvascular disease and dyslipidemia to prevent macrovascular complications. Recent clinical studies indicate that colesevelam hydrocMoride, a bile acid sequestrant, appears to be promising as an add-on therapy for T2DM patients in reducing the hyperglycemia and dyslipidemia. The objective of the paper is to review the efficacy and safety of colesevelam hydrochloride in reducing both low-density lipid cholesterol and glycosylated hemoglobin A1c levels in T2DM patients when combined with metformin, sulfonylurea or insulin.
机译:2型糖尿病(T2DM)的并发症包括大血管疾病(如冠状动脉疾病,中风或外周血管疾病)和微血管疾病(如视网膜病变,神经病变和肾病)的风险增加。血脂异常和高血糖分别会增加大血管和微血管疾病的风险。因此,T2DM的治疗必须针对高血糖症以预防微血管疾病,而血脂异常则以预防大血管并发症为目标。最近的临床研究表明,胆汁酸螯合剂考来维仑hydrocMoride在降低高血糖和血脂异常方面似乎有望作为T2DM患者的附加疗法。本文的目的是回顾与二甲双胍,磺酰脲或胰岛素联合使用时,盐酸考列维仑在降低T2DM患者的低密度脂质胆固醇和糖基化血红蛋白A1c水平方面的功效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号